In AD models, DP1 antagonism reduces cerebral β‐amyloid (Aβ) deposition and ameliorates cognitive deficits, likely through modulating microglial function to enhance Aβ clearance and suppress neuroinflammation (Stark and Penn 2024). The gene discussed is PTGDR; the disease is Alzheimer disease.